EnVVeno Medical Reports Interim Venous Ulcer Healing Data From SAVVE U.E. Pivotal Trial For VenoValve To Be Presented At Society For Vascular Surgery 2024 Annual Meeting

6/21/24 8:39:01 AM ET

$NVNO

Medical/Dental Instruments

Health Care

Get the next $NVNO alert in real time by email

91% of Venous Ulcer Patients Evaluated at One Year Have Either Fully Healed Ulcers or Ulcers That Have Improved

100% of Venous Ulcers with a Duration of One Year or Less Prior to VenoValve Surgery Have Fully Healed

89% of Venous Ulcers with a Duration of More Than One Year Prior to VenoValve Surgery Have Fully Healed or Improved

No Ulcer Recurrences

Company on Track to File Application Seeking VenoValve FDA Approval in Q4 2024

Get the next $NVNO alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$NVNO

Date	Price Target	Rating	Analyst

More analyst ratings

$NVNO
Press Releases

Fastest customizable press release news feed in the world

enVVeno Medical Reports Third Quarter 2024 Financial Results and Confirms Guidance for Release of Definitive VenoValve Data in November and Completion of FDA Premarket Approval Application for VenoValve in Q4 of this Year
Continued progress toward submission of 5th and final module of FDA premarket approval (PMA) application for VenoValve® in Q4GLP study for enVVe® transcatheter-based replacement venous valve underway; On track to file IDE approval for pivotal trial mid-2025Ended the quarter with $48.4 million cash and investments on hand sufficient to fund operations beyond expected regulatory approval of the VenoValve and start of the enVVe pivotal trial IRVINE, CA / ACCESSWIRE / October 31, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today reported financial results for the third quarter 2024."We
10/31/24 8:35:00 AM ET
$NVNO
Medical/Dental Instruments
Health Care
enVVeno Medical Successfully Initiates 6-Month Pre-Clinical GLP Study Evaluating enVVe(R)
First wave of implants successfully completed with updated delivery system performing very wellCompany on schedule to be in position to apply for approval for enVVe pivotal trial mid-2025 IRVINE, CA / ACCESSWIRE / October 28, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced the successful start to its six-month pre-clinical GLP study for enVVe, its transcatheter-delivered replacement venous valve. The first wave of implants, for the long-term subjects, was successfully completed, with the final wave for the shorter-term subjects scheduled for December. The GLP study is a
10/28/24 8:30:00 AM ET
$NVNO
Medical/Dental Instruments
Health Care
enVVeno Medical Corporation Announces Pricing of $15.0 Million Public Offering
IRVINE, CA / ACCESSWIRE / September 26, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced the pricing of an underwritten public offering led by existing institutional investors of 4,285,715 shares of its common stock (or pre-funded warrants in lieu thereof) at a public offering price of $3.50 per share. The pre-funded warrants will be immediately exercisable and may be exercised at any time until all of the pre-funded warrants are exercised in full. The purchase price of each pre-funded warrant sold in the offering will be equal to the price at which a share of common sto
9/26/24 9:18:00 PM ET
$NVNO
Medical/Dental Instruments
Health Care

EnVVeno Medical Reports Interim Venous Ulcer Healing Data From SAVVE U.E. Pivotal Trial For VenoValve To Be Presented At Society For Vascular Surgery 2024 Annual Meeting

Chat with this insight

Recent Analyst Ratings for
$NVNO

$NVNO
Press Releases

Fastest customizable press release news feed in the world

enVVeno Medical Reports Third Quarter 2024 Financial Results and Confirms Guidance for Release of Definitive VenoValve Data in November and Completion of FDA Premarket Approval Application for VenoValve in Q4 of this Year

enVVeno Medical Successfully Initiates 6-Month Pre-Clinical GLP Study Evaluating enVVe(R)

enVVeno Medical Corporation Announces Pricing of $15.0 Million Public Offering

$NVNO
Financials

Live finance-specific insights

enVVeno Medical to Host Conference Call and Webcast on September 21, 2022

$NVNO
Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G/A filed by enVVeno Medical Corporation (Amendment)

SEC Form SC 13G filed by enVVeno Medical Corporation

SEC Form SC 13G/A filed by enVVeno Medical Corporation (Amendment)

$NVNO
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Alavi Hamed sold $51,837 worth of shares (8,334 units at $6.22) and exercised 8,334 shares at a strike of $3.59 (SEC Form 4)

SEC Form 4 filed by Glynn Craig

SEC Form 4 filed by Alavi Hamed

$NVNO
Market Insights

Live Market Insights

Market-Moving News for June 21st

EnVVeno Medical shares are trading higher after the company reported interim venous ulcer healing data from the SAVVE U.E. pivotal trial for VenoValve, which will be presented at the Society for Vascular Surgery 2024 Annual Meeting.